Matches in Wikidata for { <http://www.wikidata.org/entity/Q81212513> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q81212513 description "article scientifique publié en 2008" @default.
- Q81212513 description "artículu científicu espublizáu n'abril de 2008" @default.
- Q81212513 description "im April 2008 veröffentlichter wissenschaftlicher Artikel" @default.
- Q81212513 description "scientific article published on 01 April 2008" @default.
- Q81212513 description "wetenschappelijk artikel" @default.
- Q81212513 description "наукова стаття, опублікована у квітні 2008" @default.
- Q81212513 name "If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?" @default.
- Q81212513 name "If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?" @default.
- Q81212513 type Item @default.
- Q81212513 label "If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?" @default.
- Q81212513 label "If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?" @default.
- Q81212513 prefLabel "If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?" @default.
- Q81212513 prefLabel "If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?" @default.
- Q81212513 P1433 Q81212513-2CCEA12E-164C-49E0-A660-13C22E1FEF44 @default.
- Q81212513 P1476 Q81212513-DE351FBF-A80F-4D63-BADD-FA6EC15D4242 @default.
- Q81212513 P2093 Q81212513-9E37FB84-F558-4DC8-8264-BCC76E6F3392 @default.
- Q81212513 P304 Q81212513-F126A4FC-D046-43C3-9CE7-192D525DA37D @default.
- Q81212513 P31 Q81212513-DD2C12F7-EB7D-4203-AFC6-CDCFC88150DE @default.
- Q81212513 P356 Q81212513-A7B16787-6190-4CD0-866F-C0E8AF247CA3 @default.
- Q81212513 P433 Q81212513-3E973A78-90E4-4CB8-B79E-1E1289921036 @default.
- Q81212513 P478 Q81212513-5DB53876-318E-48F6-8595-3F6BC3EE73DA @default.
- Q81212513 P577 Q81212513-FDB57B13-3D7A-4422-BA17-144FD14BBD6D @default.
- Q81212513 P698 Q81212513-FE46AB6A-A375-40BC-91C5-00E44E34CD1A @default.
- Q81212513 P356 J.PHARMTHERA.2008.03.002 @default.
- Q81212513 P698 18455801 @default.
- Q81212513 P1433 Q3378596 @default.
- Q81212513 P1476 "If a drug deemed 'safe' in nonclinical tests subsequently prolongs QT in phase 1 studies, how can its sponsor convince regulators to allow development to proceed?" @default.
- Q81212513 P2093 "Rashmi R Shah" @default.
- Q81212513 P304 "215-221" @default.
- Q81212513 P31 Q13442814 @default.
- Q81212513 P356 "10.1016/J.PHARMTHERA.2008.03.002" @default.
- Q81212513 P433 "2" @default.
- Q81212513 P478 "119" @default.
- Q81212513 P577 "2008-04-01T00:00:00Z" @default.
- Q81212513 P698 "18455801" @default.